Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Roflumilast Intermediates: Roflumilast CAS 162401-32-3 4-Amino-3,5-Dichloropyridine CAS 22889-78-7| Item | Specifications |
| Appearance | White or Almost White Crystalline Powder |
| Solubility | Free soluble in acetone, sparingly soluble in acetronitrile, slightly insoluble in anhydrous ethanol, practically insoluble in water |
| Melting Point | 157.0~162.0℃ |
| Loss on Drying | <0.50% |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤10ppm |
| Chloride | ≤0.01% |
| Identification A. UV | The wavelength of maximum absorption should be at 213~251nm |
| Identification B. IR | The IR absorption spectrum of sample corresponds to that of the reference one |
| Identification C. | It shows the reaction of Fluoride |
| Related Substances | |
| Single Impurity | ≤0.10% |
| Total Impurities | <0.50% |
| Residual Solvents | |
| Tert-Butanol | <0.10% |
| Tetrahydrofuran | <0.072% |
| Toluene | <0.089% |
| N,N-Dimethylformamide | <0.088% |
| Assay | 99.0~101.0% (Calculated on Dried Basis) |
| Test Standard | Enterprise Standard |
| Usage | API; COPD |
Description:
Specifications:
Package & Storage:
| Chemical Name | Roflumilast |
| Synonyms | 3-(Cyclopropylmethoxy)-N-(3,5-Dichloropyridin-4-yl)-4-(Ddifluoromethoxy)benzamide |
| CAS Number | 162401-32-3 |
| CAT Number | RF-PI2075 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C17H14Cl2F2N2O3 |
| Molecular Weight | 403.21 |
| Density | 1.471±0.060 g/cm3 |
| Sensitivity | Heat Sensitive |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Roflumilast (CAS: 162401-32-3) is a selective oral phosphodiesterase-4 (PDE-4) inhibitor and a benzamide compound. It was developed by the German company Altana in 1993 and is the only oral PDE-4 inhibitor used to treat respiratory tract diseases approved for sale. Roflumilast is the first drug of its kind to target severe chronic obstructive pulmonary disease (COPD), and it is also the first oral anti-inflammation drug specifically developed for COPD patients. Its unique properties can help regulate COPD: when used in combination with bronchodilators to treat extremely severe COPD patients, Roflumilast can has the advantage of further reducing symptoms and deterioration rate, thus making it the first drug that targets patients with recurring deteriorating phenotype-spAecific COPD and severe air flow obstruction related to chronic coughing and excess phlegm. Besides being a treatment for severe COPD, Roflumilast can also be used to prevent and treat livestock respiratory tract diseases, excess mucosa bronchitis cough, asthmatic bronchitis, and acute bronchitis and air sacculitis accompanied by abnormal respiratory tract secretion.
